Published Date: September, 2017
Cystic fibrosis is a genetic disease that causes continuous lung infections and breathing problem over time. It is a progressive disease. The presence of imperfect gene causes a thick, sticky buildup of mucus in the lungs, intestine liver, pancreas, and other organs. The mucus in the lungs clogs airways and traps bacteria leading to infections that causes savior lung damage, and respiratory failure. The mucus prevents in the pancreas discharge the digestive enzymes that allow the body to break down food and absorb vital nutrients. This disease is caused by mutation in gene, cystic fibrosis trans membrane conductance regulator (CFTR) is a membrane protein in vertebrates, a protein required for regulating sweat, mucus and body secretions.
Figure 1: Global Cystic fibrosis Market by Value 2015 - 2023
The global cystic fibrosis market was sized over USD 2.15 billion in 2015. The global cystic fibrosis market is projected to reach USD 6.67 billion by 2023, growing with a CAGR between 15% and 15.4% from 2017 to 2023. The global market for cystic fibrosis is driven by continued growth of the number of CF patients worldwide. Increasing awareness for cystic fibrosis therapy, technological developments in the R&D and increase in the occurrence of cystic fibrosis are some of the factors likely to drive the global cystic fibrosis market over the forecast period. However, high cost of treatment and R&D, complicated pathophysiology, and increase in genetic mutation rate are the prime restraining factors to the growth of global cystic fibrosis market. Nevertheless, rising number of initiatives taken by nonprofit organizations, and presence of flexible policies are will bring more opportunities to the global cystic fibrosis market over the forecast period.
The report segments the global cystic fibrosis market by drug class, by route of administration and by region. The global cystic fibrosis market is segmented on the basis of drug class as CFTR modulators, mucolytics, pancreatic enzyme supplements and bronchodilators. The CFTR modulator drug class was estimated to account for approximately 44%% of total CF drug revenue share in 2015. On the basis of route of administration it is segmented by inhaled drugs and oral drugs. Oral route accounted for the largest share of nearly 62.7% in 2015
Geographic Coverage and Analysis:
The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific and Rest of the World. In this section the key trends and market size for each geography is provided over the period of 2015 – 2023.
Figure 2: Global Cystic fibrosis Market by Region 2015 - 2023
North America is accounted for largest revenue share as a majority of patients affected with CF are of Caucasian descent. The Asia Pacific market region is anticipated to grow at the highest CAGR over the forecast period due to underdiagnosis and lack of country-specific CF patient registries, rising awareness about CF disorders & treatment options is expected to boost this segment over the forecast period.
The companies covered in the report include Vertex Pharmaceuticals Incorporated, Gilead, AbbVie Inc, Novartis AG., F. Hoffmann-La Roche Ltd, Alaxia, Merck & Co. Inc., AIT (Advanced Inhalation Therapies)., ALLERGAN., AstraZeneca, Teva Pharmaceutical Industries Ltd. and Alcresta Therapeutics, Inc.
The report provides deep insights on demand forecasts, market trends and micro and macro indicators. In addition, this report provides insights on the factors that are driving and restraining the demand of cystic fibrosis globally as well as regionally. Moreover, IGR-Growth Matrix analysis given in the report brings an insight on the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter’s five forces analysis and value chain analysis of cystic fibrosis. Moreover, the study highlights current market trends and provides forecast from 2017 to 2023. We also have highlighted future trends in the cystic fibrosis market that will impact the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight on the market share of the leading players. Additionally, the analysis highlights rise and fall in the market shares of the key players in the market. This report will help manufacturers, suppliers and distributors of the cystic fibrosis market to understand the present and future trends in this market and formulate their strategies accordingly.
1.1 Report Description
1.2 Research Methods
1.3 Research Approaches
2. Executive Summary
3. Global Cystic fibrosis Market Overview
3.2 Market Dynamics
3.3 Porter’s Five Forces Analysis
3.4 IGR – Growth Matrix Analysis
3.5 Competitive Landscape in the Cystic fibrosis Market
4. Global Cystic fibrosis market by Drug Class (USD Million) 2017 – 2023
4.1 CFTR Modulators
4.3 Pancreatic Enzyme Supplements
5. Global Cystic fibrosis market by Route of Administration (USD Million) 2017 – 2023
5.1 Inhaled Drugs
5.2 Oral Drugs
6. Global Cystic fibrosis Market Analysis, by Region (USD Million) 2017 – 2023
6.1 North America
6.1.1 North America Cystic fibrosis Market by Drug Class (USD Million)
6.1.2 North America Cystic fibrosis Market by Route of Administration (USD Million)
6.1.3 North America Cystic fibrosis Market by country (USD Million)
6.2.1 Europe Cystic fibrosis Market by Drug Class (USD Million)
6.2.2 Europe Cystic fibrosis Market by Route of Administration (USD Million)
6.2.3 Europe Cystic fibrosis Market by country (USD Million)
6.3.1 Asia-Pacific Cystic fibrosis Market by Drug Class (USD Million)
6.3.2 Asia-Pacific Cystic fibrosis Market by Route of Administration (USD Million
6.3.3 Asia-Pacific Cystic fibrosis Market by country (USD Million)
6.4 Rest of the World (RoW)
6.4.1 RoW Cystic fibrosis Market by Drug Class (USD Million)
6.4.2 RoW Cystic fibrosis Market by Route of Administration (USD Million)
6.4.3 RoW Cystic fibrosis Market by Sub-region (USD Million)
7. Company Profiles
7.1 Vertex Pharmaceuticals Incorporated
7.3 AbbVie, Inc.
7.4 Novartis AG
7.5 F. Hoffmann-La Roche Ltd
7.7 Merck & Co. Inc.
7.8 AIT (Advanced Inhalation Therapies)
7.11 Teva Pharmaceutical Industries Ltd
Get free analyst support for the queries before and post purchasing report.
Be assured of 100% customer satisfaction about the research and get 24X7 customer support.
Infinium has achieved over 400%+ growth in its repository and revenue over the last 2 years. Yes, we are proud to say we are growing at a great pace and becoming a trusted partner among our clients.
sign up for our newsletter